Drug intelligence / Profile preview

VTX3936

Development stage: Preclinical
Lead developer: Ventyx Biosciences
Modality: Small Molecules
Administration: Oral

Overview

VTX3936 is a clinical-stage oral small molecule therapeutic that was part of Ventyx Biosciences' pipeline, a company acquired by Eli Lilly and Company. It is being developed for inflammatory-mediated diseases. While Ventyx's pipeline includes NLRP3, TYK2, and S1P1R inhibitors, the specific mechanism of action for VTX3936 has not been publicly disclosed in the provided context.

Beyond the preview

Go deeper on VTX3936.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on VTX3936.

Explore the full profile